Technical Analysis for EPZM - Epizyme, Inc.

Grade Last Price % Change Price Change
grade D 12.83 -2.14% -0.28
EPZM closed down 2.14 percent on Tuesday, July 23, 2019, on 71 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Earnings due: Aug 1

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical EPZM trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
Crossed Above 50 DMA Bullish -2.14%
Inside Day Range Contraction 0.79%
MACD Bearish Centerline Cross Bearish 0.39%
Down 3 Days in a Row Weakness 2.07%
Fell Below 20 DMA Bearish -0.77%
Fell Below 50 DMA Bearish -0.77%
MACD Bearish Signal Line Cross Bearish -0.77%
180 Bearish Setup Bearish Swing Setup -0.77%
20 DMA Support Bullish -6.01%

Older signals for EPZM ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Epizyme, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, planning, and commercialization of various personalized therapeutics for the treatment of patients with genetically defined cancers. Its principal product candidates under development include EPZ-5676, an intravenously administered small molecule inhibitor of DOT1L that is in Phase I clinical trials for the treatment of mixed lineage rearranged leukemia (MLL-r); and EPZ-6438, an orally available small molecule inhibitor of EZH2 for the treatment of non-Hodgkin lymphoma patients caused by an oncogenic point mutation in EZH2. The company has strategic collaboration and license agreements with Celgene Corporation and Celgene International Sàrl, as well as Glaxo Group Limited to discover, develop, and commercialize small molecule HMT inhibitors; and Eisai Co., Ltd. (Eisai) to license its EZH2 program. It also has a companion diagnostic collaboration with Abbott Molecular Inc. for the development of a companion diagnostic to identify patients with the MLL-r genetic alteration targeted by EPZ-5676; and with Roche Molecular Systems, Inc., as well as with Eisai for the development and commercialization of a companion diagnostic for use with EPZ-6438 product candidate. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Biotechnology Life Sciences Cancers Leukemia Celgene Non Hodgkin Lymphoma Eisai Ezh2 Treatment Of Non Hodgkin Lymphoma
Is EPZM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 16.59
52 Week Low 5.14
Average Volume 909,675
200-Day Moving Average 10.7809
50-Day Moving Average 13.0812
20-Day Moving Average 13.144
10-Day Moving Average 13.168
Average True Range 0.6735
ADX 10.56
+DI 23.0641
-DI 25.8871
Chandelier Exit (Long, 3 ATRs ) 14.5695
Chandelier Exit (Short, 3 ATRs ) 13.9705
Upper Bollinger Band 14.0641
Lower Bollinger Band 12.2239
Percent B (%b) 0.33
BandWidth 14.000304
MACD Line -0.0717
MACD Signal Line 0.0104
MACD Histogram -0.0821
Fundamentals Value
Market Cap 750.12 Million
Num Shares 58.5 Million
EPS -2.07
Price-to-Earnings (P/E) Ratio -6.20
Price-to-Sales 55.00
Price-to-Book 6.25
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.63
Resistance 3 (R3) 13.64 13.39 13.49
Resistance 2 (R2) 13.39 13.19 13.38 13.45
Resistance 1 (R1) 13.11 13.06 12.99 13.10 13.40
Pivot Point 12.86 12.86 12.80 12.85 12.86
Support 1 (S1) 12.58 12.66 12.46 12.57 12.26
Support 2 (S2) 12.33 12.53 12.32 12.21
Support 3 (S3) 12.05 12.33 12.17
Support 4 (S4) 12.04